BNP Paribas Financial Markets
KLDO

BNP Paribas Financial Markets’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

BNP Paribas Financial Markets’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,935
Closed -$3.19K – 4333
2022
Q1 		$3.19K Sell
1,935
-2,498
-56% -$4.46K ﹤0.01% 3882
2021
Q4 		$10.6K Buy
4,433
+705
+19% +$2.87K ﹤0.01% 3891
2021
Q3 		$20.4K Buy
3,728
+2,941
+374% +$18.2K ﹤0.01% 3636
2021
Q2 		$5.86K Sell
787
-1,012
-56% -$7.17K ﹤0.01% 3791
2021
Q1 		$14.6K Sell
1,799
-387
-18% -$4.22K ﹤0.01% 3798
2020
Q4 		$19.9K Sell
2,186
-405
-16% -$3.32K ﹤0.01% 3851
2020
Q3 		$28.7K Buy
2,591
+2,205
+571% +$15.3K ﹤0.01% 3704
2020
Q2 		$2.87K Sell
386
-3,123
-89% -$20.9K ﹤0.01% 4143
2020
Q1 		$21.6K Buy
3,509
+1,857
+112% +$12.1K ﹤0.01% 3892
2019
Q4 		$8.29K Buy
1,652
+1,402
+561% +$8.91K ﹤0.01% 4148
2019
Q3 		$1.88K Buy
250
+237
+1,823% +$2.06K ﹤0.01% 4371
2019
Q2 		$151 Buy
+13
New +$189 ﹤0.01% 4466

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BNP Paribas Financial Markets's KLDO Position: Q2 2022 in Review

BNP Paribas Financial Markets sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 1,935 shares — an estimated $3.19K sold.

BNP Paribas Financial Markets first reported a position in KLDO in Q2 2019 and held it in 12 quarters. The position peaked at $28.7K in Q3 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • BNP Paribas Financial Markets reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 1,935 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $3.19K.
  • BNP Paribas Financial Markets first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • BNP Paribas Financial Markets's Kaleido Biosciences, Inc. Common Stock position peaked at $28.7K in Q3 2020.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2022, filed 12 Aug 2022.